Dr. Christopher Janik is a pharmacist who is specialized in Nuclear in Cheektowaga, New York. Patients can reach him at 840 Aero Dr, Suite 150, Cheektowaga or contact him on 716-810-0688. Active license number of Dr. Christopher Janik is 047930 for Nuclear in New York. Dr. Christopher Janik is a licensed pharmacist who has demonstrated specialized knowledge and skill in procurement, compounding, quality control testing, dispensing, distribution, and monitoring of radiopharmaceuticals.
Complete Profile:
Dr. Christopher Janik speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Christopher Janik
Specialization:
Nuclear
Credentials:
PHARMD
Gender:
Male
Location:
840 Aero Dr, Suite 150, Cheektowaga, New York, 14225-1451
Phone:
716-810-0688
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Christopher Janik are as mentioned below.
NPI Number:
1033329172
NPI Enumeration Date:
23 May, 2007
NPI Last Update On:
05 May, 2020
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Christopher Janik are as mentioned below.
Specialization
License Number
State
Status
Nuclear
047930
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
Uscg Academy, 15 Mohegan Ave New London, Connecticut
Zip:
06340
Phone Number:
860-701-6614
Fax Number:
--
Patients can reach Dr. Christopher Janik at 840 Aero Dr, Suite 150, Cheektowaga, New York or can call on phone at 716-810-0688.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.